About this trial
The goal of this observational study is to explore the incidence and effect on prognosis of coronary microvascular dysfunction in patients present of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \>0.80.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
presence of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) >0.80
Disqualifiers
acute myocardial infarction
significant valvular heart disease
advanced chronic kidney disease
patients with significant epicardial coronary artery stenosis (>70% in major vessels by diagnostic coronary angiography) needing percutaneous coronary intervention
Trial population
Patients present of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \>0.80
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
MACE in 12 months
major adverse cardiovascular events 12 months, including cardiac death, myocardial infarction, and readmission for angina.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.